Skip to main content
Erschienen in: AIDS and Behavior 9/2021

11.06.2021 | Original Paper

Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention

verfasst von: Marla J. Husnik, Elizabeth R. Brown, Sufia S. Dadabhai, Zakir Gaffoor, Nitesha Jeenarain, Flavia Matovu Kiweewa, Edward Livant, Leila E. Mansoor, Brenda Gati Mirembe, Thesla Palanee-Phillips, Devika Singh, Samantha Siva, Lydia Soto-Torres, Ariane van der Straten, Jared M. Baeten, for the M. T. N.-020/ASPIRE Study Team

Erschienen in: AIDS and Behavior | Ausgabe 9/2021

Einloggen, um Zugang zu erhalten

Abstract

Understanding characteristics associated with adherence to pre-exposure prophylaxis (PrEP) methods for HIV-1 prevention may assist with optimizing implementation efforts. The dapivirine vaginal ring is a novel topical PrEP delivery method. Using data from a randomized, double-blind, placebo-controlled, phase III trial of the dapivirine vaginal ring conducted in four African countries, generalized estimating equation models were used to evaluate correlates of ring adherence. Two levels of quarterly dapivirine blood plasma, and dapivirine released from returned rings defined measures of adherence for recent and cumulative use, respectively. Time on study, calendar time, primary partner knowledge that the participant was taking part in the study, and use of long-acting contraceptive methods were associated with ring adherence whereas younger age, ring worries, condom use, episodes of menstrual bleeding and vaginal washing were associated with non-adherence. These findings may be useful for recruitment into future clinical studies and dapivirine ring implementation efforts.
Literatur
3.
Zurück zum Zitat Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410.CrossRef Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410.CrossRef
4.
Zurück zum Zitat Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381:2083–90.CrossRef Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381:2083–90.CrossRef
5.
Zurück zum Zitat Grant RM, Lama JR, Anderson PL, et al. Pre-exposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99.CrossRef Grant RM, Lama JR, Anderson PL, et al. Pre-exposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99.CrossRef
6.
Zurück zum Zitat Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir based pre-exposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372:509–18.CrossRef Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir based pre-exposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372:509–18.CrossRef
7.
Zurück zum Zitat Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.CrossRef Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.CrossRef
8.
Zurück zum Zitat Rees H, Delany-Moretlwe S, Lombard C, et al. FACTS 001 phase III trial of pericoital tenofovir 1% gel for HIV prevention in women CROI 2015: presented at the conference on retroviruses and opportunistic infections, Boston, February 23–26, 2015. Abstract. Rees H, Delany-Moretlwe S, Lombard C, et al. FACTS 001 phase III trial of pericoital tenofovir 1% gel for HIV prevention in women CROI 2015: presented at the conference on retroviruses and opportunistic infections, Boston, February 23–26, 2015. Abstract.
9.
Zurück zum Zitat Nel A, van Niekerk N, Kapiga S, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375:2133–43.CrossRef Nel A, van Niekerk N, Kapiga S, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375:2133–43.CrossRef
10.
Zurück zum Zitat Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375:2121–32.CrossRef Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375:2121–32.CrossRef
12.
Zurück zum Zitat Husnik MJ, Brown ER, Marzinke M, et al. Implementation of a novel adherence monitoring strategy in a phase III, blinded, placebo-controlled, HIV-1 prevention clinical trial. J Acquir Immune Defic Syndr. 2017;76:330–7.CrossRef Husnik MJ, Brown ER, Marzinke M, et al. Implementation of a novel adherence monitoring strategy in a phase III, blinded, placebo-controlled, HIV-1 prevention clinical trial. J Acquir Immune Defic Syndr. 2017;76:330–7.CrossRef
13.
Zurück zum Zitat Seserko LA, Emory JF, Hendrix CW, et al. The development and validation of an UHPLC-MS/MS method for the rapid quantification of the antiretroviral agent dapivirine in human plasma. Bioanalysis. 2013;5(22):2771–83.CrossRef Seserko LA, Emory JF, Hendrix CW, et al. The development and validation of an UHPLC-MS/MS method for the rapid quantification of the antiretroviral agent dapivirine in human plasma. Bioanalysis. 2013;5(22):2771–83.CrossRef
14.
Zurück zum Zitat Podsadecki TJ, Vrijens BC, Tousset EP, et al. “White coat compliance” limits the reliability of therapeutic drug monitoring in HIV-1—infected patients. HIV Clin Trials. 2008;9(4):238–46.CrossRef Podsadecki TJ, Vrijens BC, Tousset EP, et al. “White coat compliance” limits the reliability of therapeutic drug monitoring in HIV-1—infected patients. HIV Clin Trials. 2008;9(4):238–46.CrossRef
15.
Zurück zum Zitat Nel A, Haazen W, Nuttall J, et al. A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women. AIDS. 2014;28(10):1479–87.CrossRef Nel A, Haazen W, Nuttall J, et al. A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women. AIDS. 2014;28(10):1479–87.CrossRef
16.
Zurück zum Zitat Nel AM, Haazen W, Nuttall JP, et al. Pharmacokinetics and safety assessment of anti-HIV dapivirine vaginal microbicide rings with multiple dosing. J AIDS Clin Res. 2014;5:355. Nel AM, Haazen W, Nuttall JP, et al. Pharmacokinetics and safety assessment of anti-HIV dapivirine vaginal microbicide rings with multiple dosing. J AIDS Clin Res. 2014;5:355.
17.
Zurück zum Zitat Nel A, Bekker LG, Bukusi E, et al. Safety, acceptability and adherence of dapivirine vaginal ring in a microbicide clinical trial conducted in multiple countries in sub-Saharan Africa. PLoS ONE. 2016;11:e0147743.CrossRef Nel A, Bekker LG, Bukusi E, et al. Safety, acceptability and adherence of dapivirine vaginal ring in a microbicide clinical trial conducted in multiple countries in sub-Saharan Africa. PLoS ONE. 2016;11:e0147743.CrossRef
18.
Zurück zum Zitat Spence P, Nel A, van Niekerk N, et al. Post-use assay of vaginal rings (VRs) as a potential measure of clinical trial adherence. J Pharm Biomed Anal. 2016;125:94–100.CrossRef Spence P, Nel A, van Niekerk N, et al. Post-use assay of vaginal rings (VRs) as a potential measure of clinical trial adherence. J Pharm Biomed Anal. 2016;125:94–100.CrossRef
19.
Zurück zum Zitat Brown ER, Hendrix CW, van der Straten A, et al. Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial. J Int AIDS Soc. 2020;23:11. Brown ER, Hendrix CW, van der Straten A, et al. Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial. J Int AIDS Soc. 2020;23:11.
20.
Zurück zum Zitat Cohen R, Rodriguez R. "High-Performance Statistical Modeling". In: Proceedings of the SAS Global Forum Conference. Cary, NC: SAS Institute Inc; 2013 Cohen R, Rodriguez R. "High-Performance Statistical Modeling". In: Proceedings of the SAS Global Forum Conference. Cary, NC: SAS Institute Inc; 2013
21.
Zurück zum Zitat Weinrib R, Minnis A, Agot K, et al. End-users’ product preference across three multipurpose prevention technology delivery forms: baseline results from young women in Kenya and South. AIDS Behav. 2018;22:133.CrossRef Weinrib R, Minnis A, Agot K, et al. End-users’ product preference across three multipurpose prevention technology delivery forms: baseline results from young women in Kenya and South. AIDS Behav. 2018;22:133.CrossRef
22.
Zurück zum Zitat Montgomery ET, van der Straten A, Chitukuta M, et al. Acceptability and use of a dapivirine vaginal ring in a phase III trial. AIDS. 2017;31(8):1159–67.CrossRef Montgomery ET, van der Straten A, Chitukuta M, et al. Acceptability and use of a dapivirine vaginal ring in a phase III trial. AIDS. 2017;31(8):1159–67.CrossRef
23.
Zurück zum Zitat Montgomery ET, van der Straten A, Cheng H, et al. Vaginal ring adherence in sub-Saharan Africa: expulsion, removal, and perfect use. AIDS Behav. 2012;7:1787–98.CrossRef Montgomery ET, van der Straten A, Cheng H, et al. Vaginal ring adherence in sub-Saharan Africa: expulsion, removal, and perfect use. AIDS Behav. 2012;7:1787–98.CrossRef
24.
Zurück zum Zitat van der Straten A, Montgomery E, Cheng H, et al. High acceptability of a vaginal ring intended as a microbicide delivery method for HIV prevention in African women. AIDS Behav. 2012;16:1775–86.CrossRef van der Straten A, Montgomery E, Cheng H, et al. High acceptability of a vaginal ring intended as a microbicide delivery method for HIV prevention in African women. AIDS Behav. 2012;16:1775–86.CrossRef
25.
Zurück zum Zitat Karim AQ, Karim AS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74.CrossRef Karim AQ, Karim AS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74.CrossRef
26.
Zurück zum Zitat Donnell D, Baeten JM, Bumpus NN, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;66:340–8.CrossRef Donnell D, Baeten JM, Bumpus NN, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;66:340–8.CrossRef
27.
Zurück zum Zitat Blanc AK, Tsui AO, Croft TN, Trevitt JL. Patterns and trends in adolescents’ contraceptive use and discontinuation in developing countries and comparisons with adult women. Int Perspect Sex Reprod Health. 2009;35:63–71.CrossRef Blanc AK, Tsui AO, Croft TN, Trevitt JL. Patterns and trends in adolescents’ contraceptive use and discontinuation in developing countries and comparisons with adult women. Int Perspect Sex Reprod Health. 2009;35:63–71.CrossRef
28.
Zurück zum Zitat Evans D, Menezes C, Mahomed K, et al. Treatment outcomes of HIV-infected adolescents attending public-sector HIV clinics across Gauteng and Mpumalanga. South Africa AIDS Res Hum Retroviruses. 2013;29:892–900.CrossRef Evans D, Menezes C, Mahomed K, et al. Treatment outcomes of HIV-infected adolescents attending public-sector HIV clinics across Gauteng and Mpumalanga. South Africa AIDS Res Hum Retroviruses. 2013;29:892–900.CrossRef
29.
Zurück zum Zitat van der Straten A, Stadler J, Montgomery E, et al. Women’s experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PLoS ONE. 2014;9(2):e89118.CrossRef van der Straten A, Stadler J, Montgomery E, et al. Women’s experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PLoS ONE. 2014;9(2):e89118.CrossRef
31.
Zurück zum Zitat Browne EN, Mayo AJ, Montgomery E, et al. Acceptability of and adherence to the dapivirine vaginal ring for HIV 1 prevention. Adherence 2019, June 17, 2019, Miami, FL. Browne EN, Mayo AJ, Montgomery E, et al. Acceptability of and adherence to the dapivirine vaginal ring for HIV 1 prevention. Adherence 2019, June 17, 2019, Miami, FL.
32.
Zurück zum Zitat van der Straten A, Browne E, Shapley-Quinn MK, et al. First impressions matter: how initial worries influence adherence to the dapivirine vaginal ring. J Acquir Immune Defic Syndr. 2019;81:304–10.CrossRef van der Straten A, Browne E, Shapley-Quinn MK, et al. First impressions matter: how initial worries influence adherence to the dapivirine vaginal ring. J Acquir Immune Defic Syndr. 2019;81:304–10.CrossRef
33.
Zurück zum Zitat Duby Z, Katz AWK, Browne EN, et al. Hygiene, blood flow, and vaginal overload: why women removed an HIV prevention vaginal ring during menstruation in Malawi, South Africa, Uganda and Zimbabwe. AIDS Behav. 2019;24:617–28.CrossRef Duby Z, Katz AWK, Browne EN, et al. Hygiene, blood flow, and vaginal overload: why women removed an HIV prevention vaginal ring during menstruation in Malawi, South Africa, Uganda and Zimbabwe. AIDS Behav. 2019;24:617–28.CrossRef
34.
Zurück zum Zitat Balkus JE, Palanee-Phillips T, Reddy K, et al. Dapivirine vaginal ring use does not diminish the effectiveness of hormonal contraception. Acquir Immune Defic Syndr. 2017;76:e47–51.CrossRef Balkus JE, Palanee-Phillips T, Reddy K, et al. Dapivirine vaginal ring use does not diminish the effectiveness of hormonal contraception. Acquir Immune Defic Syndr. 2017;76:e47–51.CrossRef
35.
Zurück zum Zitat Mensch BS, Richardson BA, Husnik M, et al. Vaginal ring use in a phase 3 microbicide trial: a comparison of objective measures and self-reports of non-adherence in ASPIRE. AIDS Behav. 2019;23:504–12.CrossRef Mensch BS, Richardson BA, Husnik M, et al. Vaginal ring use in a phase 3 microbicide trial: a comparison of objective measures and self-reports of non-adherence in ASPIRE. AIDS Behav. 2019;23:504–12.CrossRef
Metadaten
Titel
Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention
verfasst von
Marla J. Husnik
Elizabeth R. Brown
Sufia S. Dadabhai
Zakir Gaffoor
Nitesha Jeenarain
Flavia Matovu Kiweewa
Edward Livant
Leila E. Mansoor
Brenda Gati Mirembe
Thesla Palanee-Phillips
Devika Singh
Samantha Siva
Lydia Soto-Torres
Ariane van der Straten
Jared M. Baeten
for the M. T. N.-020/ASPIRE Study Team
Publikationsdatum
11.06.2021
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 9/2021
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-021-03231-x

Weitere Artikel der Ausgabe 9/2021

AIDS and Behavior 9/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.